RH&P Global Life Sciences Fund I DIS EUR

Reference Data

ISIN LU1178102759
Valor Number 26808198
Bloomberg Global ID
Fund Name RH&P Global Life Sciences Fund I DIS EUR
Fund Provider RH&PARTNER Investment Funds Basel, Switzerland
Phone: +41 61 378 83 63
E-Mail: info@rh-finanz.ch
Web: https://www.rh-finanz.ch
Fund Provider RH&PARTNER Investment Funds
Representative in Switzerland ACOLIN Fund Services AG
Zürich
Phone: +41 44 396 96 96
Distributor(s) Banque Pictet & Cie SA Credit Suisse
Zürich UBS
n/a Vontobel
n/a
Asset Class Equities
EFC Category
Distribution Policy Distribution
Home Country Luxembourg
Issuing Condition The fund management company and/or distributor charges an issuing commission (different commissions can be charged for the same fund depending on the sales channel)
Redemption Condition The fund management company and/or distributor charges a redemption commission (different commissions can be charged for the same fund depending on the sales channel)
Investment Strategy *** N/A
Peculiarities

Fund Prices

Current Price * 110.47 EUR 10.12.2025
Previous Price * 109.55 EUR 09.12.2025
52 Week High * 114.47 EUR 27.11.2025
52 Week Low * 80.97 EUR 08.04.2025
NAV * 110.47 EUR 10.12.2025
Issue Price *
Redemption Price *
Closing Price *
Indicative Minimum Price
Fund Assets *** 60,936,575
Unit/Share Assets *** 1,137,269
Trading Information SIX

Performance

YTD Performance +20.75% 31.12.2024
10.12.2025
YTD Performance (in CHF) +20.16% 31.12.2024
10.12.2025
1 month +4.75% 10.11.2025
10.12.2025
3 months +14.52% 10.09.2025
10.12.2025
6 months +21.60% 10.06.2025
10.12.2025
1 year +13.71% 10.12.2024
10.12.2025
2 years +31.01% 11.12.2023
10.12.2025
3 years +15.01% 12.12.2022
10.12.2025
5 years +0.87% 10.12.2020
10.12.2025

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

Charles River Laboratories International Inc 4.53%
Bio-Techne Corp 4.46%
Nektar Therapeutics 4.36%
Illumina Inc 3.93%
Exelixis Inc 3.87%
Alkermes PLC 3.72%
IQVIA Holdings Inc 3.65%
Biogen Inc 3.59%
Amgen Inc 3.57%
Incyte Corp 3.53%
Last data update 30.04.2021

Cost / Risk

TER *** 1.469%
TER date *** 31.08.2025
Performance Fee ***
PTR
Max. Management Fee *** 0.70%
Ongoing Charges *** 1.54%
SRRI ***
SRRI date *** 30.11.2025

Breakdowns

Equity Countries ***

Equity Sectors ***

Bond Sectors ***


* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)